Literature DB >> 34903603

Comprehensive Analysis of Alternative Splicing in Gastric Cancer Identifies Epithelial-Mesenchymal Transition Subtypes Associated with Survival.

Yukyung Jun1,2,3, Yun-Suhk Suh1,4,5,6, SungHee Park1, Jieun Lee6, Jong-Il Kim7, Sanghyuk Lee2,8, Wan-Ping Lee1,9,10, Olga Anczuków1, Han-Kwang Yang4,5,11, Charles Lee1,2,8,9.   

Abstract

Alternatively spliced RNA isoforms are a hallmark of tumors, but their nature, prevalence, and clinical implications in gastric cancer have not been comprehensively characterized. We systematically profiled the splicing landscape of 83 gastric tumors and matched normal mucosa, identifying and experimentally validating eight splicing events that can classify all gastric cancers into three subtypes: epithelial-splicing (EpiS), mesenchymal-splicing (MesS), and hybrid-splicing. These subtypes were associated with distinct molecular signatures and epithelial-mesenchymal transition markers. Subtype-specific splicing events were enriched in motifs for splicing factors RBM24 and ESRP1, which were upregulated in MesS and EpiS tumors, respectively. A simple classifier based only on RNA levels of RBM24 and ESRP1, which can be readily implemented in the clinic, was sufficient to distinguish gastric cancer subtypes and predict patient survival in multiple independent patient cohorts. Overall, this study provides insights into alternative splicing in gastric cancer and the potential clinical utility of splicing-based patient classification. SIGNIFICANCE: This study presents a comprehensive analysis of alternative splicing in the context of patient classification, molecular mechanisms, and prognosis in gastric cancer. ©2021 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34903603     DOI: 10.1158/0008-5472.CAN-21-2117

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  TP53-mediated miR-2861 promotes osteogenic differentiation of BMSCs by targeting Smad7.

Authors:  Xian-Pei Zhou; Qi-Wei Li; Zi-Zhen Shu; Yang Liu
Journal:  Mol Cell Biochem       Date:  2021-10-28       Impact factor: 3.396

Review 2.  RBM24 in the Post-Transcriptional Regulation of Cancer Progression: Anti-Tumor or Pro-Tumor Activity?

Authors:  De-Li Shi
Journal:  Cancers (Basel)       Date:  2022-04-06       Impact factor: 6.639

3.  Multi-omics analysis reveals RNA splicing alterations and their biological and clinical implications in lung adenocarcinoma.

Authors:  Quanyou Wu; Lin Feng; Yaru Wang; Yousheng Mao; Xuebing Di; Kaitai Zhang; Shujun Cheng; Ting Xiao
Journal:  Signal Transduct Target Ther       Date:  2022-08-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.